Mark Doerr

Mark Doerr is a principal and senior research analyst at Tech Insider covering medical technology companies with a focus on cardiovascular and related therapeutic technology. Mark leverages his prior experience as the director of marketing and business development at a medical device company, along with an extensive network of physician and industry relationships, to provide a unique perspective on the medtech sector. Prior to joining Tech Insider in 2011 he covered medical technology for four years at Craig-Hallum Capital, and has in total 20 years of financial and medtech industry experience.

Winnebago Industries Reports Another Excellent Quarter

Winnebago Industries reported another excellent quarter to close out fiscal 2013. We plan to modestly increase our fair value estimate to reflect more expense leverage and a higher mid-cycle margin than previously modeled. Revenue for the quarter increased 31.8% year over year thanks to a 43.1% rise in motor home deliveries to 1,890 units. For…

Read More

Precision Castparts Posts Record Sales in Second Quarter

Precision Castparts reported record sales of $2.36 billion in the second quarter of fiscal 2014, a 23% increase including 6% organic. The surprise, once again, was the 170-basis-point increase in operating margins to 27.5%, as the company has quickly brought Titanium Metals’ midteens operating margins closer to Precision’s mid-20s levels, leaving no doubt regarding the execution…

Read More

INFA Reports Strong Quarter Despite Macro Headwinds

Informatica reported solid first-quarter results with revenue growth slightly exceeding expectations, as increased hiring and investment weighed on margins.  The firm grew revenue 9.3% from the year-ago period to $214.3 million, 5% ahead of our model. Informatica changed the way it reports revenues by giving more details, which we find helpful. Service revenue was strong,…

Read More

Silgan Posts Dismal Quarter; Lowers Full Year Guidance

After reviewing Silgan’s disappointing third-quarter results, we are maintaining our $42 per share fair value estimate as well as our narrow economic moat rating. We are, however, reducing our full-year EPS estimate to $2.78 after management lowered guidance to $2.75-$2.85 from $3.00-$3.15. Our longer-term thesis on Silgan is that, while the company currently possesses a…

Read More